ClinicalTrials.gg
CompletedNCT01113931Updated Jan 27, 2012Results posted

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

A Phase 3 interventional study of Doxycyline Hyclate tablet and Vibramycin (doxycyline hyclate) capsule in Urogential Chlamydia Trachomatis Infection, sponsored by Warner Chilcott. Completed at 43 sites in United States. Open to participants aged 19 Years to 45 Years. Per ClinicalTrials.gov, last updated 2012-01-27.

Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
495
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies in Chlamydia Infections with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Chlamydia Infections · United States.

Enrollment
29th of 56
495 · median 511
Started
2010
with 4 others
Phase 3
9 of 79
none open now
Registered
24th of 79
by date

Among the 79 studies in Chlamydia Infections with a site in United States, this one is the 29th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2010, is one of 9 in phase 3, and was the 24th registered.

Chlamydia Infections

134 studies on the registry are indexed under Chlamydia Infections; 23 are open to participants now.

Browse Chlamydia Infections studies →

Open to participants now

8 of the 79 studies in Chlamydia Infections with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Chlamydia Infections studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 19 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Chlamydia Infections with a site in United States, or all of them as a file.
02

Study summary

Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days, for the treatment of uncomplicated urogenital Chlamydia trachomatis infection. Primary efficacy endpoint is microbiological cure at Day 28. Safety assessments are adverse events, changes in vital signs and laboratory test results.

03

Conditions studied

  • Urogential Chlamydia Trachomatis Infection

Browse trials for

Keywords

  • Chlamydia
04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19-45 years of age, male or female
  • presumed diagnosis of urogenital C. trachomatis infection
  • use condoms during sexual activity during study (enrollment thru day 28)

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis pelvic inflammatory disease or epididymitis at baseline
  • Diagnosis of N. gonorrhoea
  • infection
  • Active or C infection
  • Prior hysterectomy (partial or total)
  • Treatment with antimicrobial therapy with known activity against urogenital C. trachomatis within 28 days of enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
495 participants (actual)

Study arms

  • Experimental
    Doxycycline Hyclate 200 mg tablet

    Once daily

    Drug: Doxycyline Hyclate tablet

  • Active comparator
    Vibramycin 100 mg capsule

    Twice daily

    Drug: Vibramycin (doxycyline hyclate) capsule

Interventions

  • DrugDoxycyline Hyclate tablet

    200 mg tablet, once daily for 7 days

    Also known as: WC2031

  • 100 mg capsule, twice daily for 7 days, over-encapsulated

    Also known as: doxycycline

06

What researchers measure

Primary outcomes

  1. Microbiological Cure Rate

    Percentage of Subjects in mITT Population with Microbiological Cure defined as a negative result for C. trachomatis as determined by GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test) at Day 28

    Time frame: Day 28

Secondary outcomes

  1. Microbiological Cure and Clinical Cure of C. Trachomatis, Day 28, Clinically Evaluable Population, Percentage Participants Cured

    Microbiological cure (defined as a negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test and clinical cure (for males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritus and urethral discharge, and resolution of exam finding of urethral discharge; for females resolution of exam finding of endocervical discharge) at Day 28

    Time frame: End of Study (Day 28)

  2. Microbiological Cure C. Trachomatis and M. Genitalium, M. Genitalium Coinfected Population, Day 28, Percentage Participants Cured

    Percentage Subjects Cured of both M. genitalium and C. trachomatis M. genitalium co-infected population: microbiological cure for both at Day 28, defined as negative PCR (polymerase chain reaction) for M. genitalium and negative GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) for C. trachomatis at Day 28

    Time frame: End of Study (Day 28)

  3. Microbiological Cure C. Trachomatis, N. Gonorrhoea Negative Population, Day 28, Percentage Participants Cured

    Percentage Participants cured in N. gonorrhoea Negative Population: cured defined as both microbiological cure (negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) and clinical cure (males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritis and urethral discharge, and resolution of exam finding of urethral discharge; females - resolution of exam finding of endocervical discharge) at Day 28

    Time frame: Day 28

07

Results

Posted Jan 27, 2012

Participant flow

Enrollment period began 7 Apr '10

Participant flow — Overall Study
MilestoneDoxycycline HyclateVibramycin
Started247248
Safety population246248
Mitt population188190
Completed228231
Not completed1917
Withdrew: Adverse event22
Withdrew: Physician decision02
Withdrew: Lost to follow-up129
Withdrew: Various24
Withdrew: Withdrawal by subject30

Outcome measures

PrimaryMicrobiological Cure Rate

Percentage of Subjects in mITT Population with Microbiological Cure defined as a negative result for C. trachomatis as determined by GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test) at Day 28

Time frame:
Day 28
Reported as:
Number · percentage of participants cured
Microbiological Cure Rate
percentage of participants curedDoxycycline HyclateVibramycin
Microbiological Cure Rate94.9 (91.5 to 98.3)94.6 (91.2 to 98.0)
Statistical analysis
  • Doxycycline Hyclate vs Vibramycin · Difference in percent cure rates: 0.3 · 95% CI -4.6 to 5.1
SecondaryMicrobiological Cure and Clinical Cure of C. Trachomatis, Day 28, Clinically Evaluable Population, Percentage Participants Cured

Microbiological cure (defined as a negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test and clinical cure (for males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritus and urethral discharge, and resolution of exam finding of urethral discharge; for females resolution of exam finding of endocervical discharge) at Day 28

Time frame:
End of Study (Day 28)
Reported as:
Number · Percentage Particpants Cured
Microbiological Cure and Clinical Cure of C. Trachomatis, Day 28, Clinically Evaluable Population, Percentage Participants Cured
Percentage Particpants CuredDoxycycline HyclateVibramycin
Microbiological Cure and Clinical Cure of C. Trachomatis, Day 28, Clinically Evaluable Population, Percentage Participants Cured80.068.6
SecondaryMicrobiological Cure C. Trachomatis and M. Genitalium, M. Genitalium Coinfected Population, Day 28, Percentage Participants Cured

Percentage Subjects Cured of both M. genitalium and C. trachomatis M. genitalium co-infected population: microbiological cure for both at Day 28, defined as negative PCR (polymerase chain reaction) for M. genitalium and negative GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) for C. trachomatis at Day 28

Time frame:
End of Study (Day 28)
Reported as:
Number · Percentage Participants Cured
Microbiological Cure C. Trachomatis and M. Genitalium, M. Genitalium Coinfected Population, Day 28, Percentage Participants Cured
Percentage Participants CuredDoxycycline HyclateVibramycin
Microbiological Cure C. Trachomatis and M. Genitalium, M. Genitalium Coinfected Population, Day 28, Percentage Participants Cured38.518.2
SecondaryMicrobiological Cure C. Trachomatis, N. Gonorrhoea Negative Population, Day 28, Percentage Participants Cured

Percentage Participants cured in N. gonorrhoea Negative Population: cured defined as both microbiological cure (negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) and clinical cure (males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritis and urethral discharge, and resolution of exam finding of urethral discharge; females - resolution of exam finding of endocervical discharge) at Day 28

Time frame:
Day 28
Reported as:
Number · Percentage Participants Cured
Microbiological Cure C. Trachomatis, N. Gonorrhoea Negative Population, Day 28, Percentage Participants Cured
Percentage Participants CuredDoxycycline HyclateVibramycin
Microbiological Cure C. Trachomatis, N. Gonorrhoea Negative Population, Day 28, Percentage Participants Cured94.9 (91.4 to 98.3)94.6 (91.2 to 98.0)
Statistical analysis
  • Doxycycline Hyclate vs Vibramycin · Difference in percent cure rates: 0.2 · 95% CI -4.6 to 5.1

Adverse events

Collected over 28 day treatment period. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxycycline Hyclate—0/246 (0%)84/246 (34.1%)
Vibramycin—0/248 (0%)129/248 (52%)
Most frequent other events
Most frequent other events
EventDoxycycline HyclateVibramycin
NauseaGastrointestinal disorders33/24651/248
VomitingGastrointestinal disorders20/24630/248
HeadacheNervous system disorders5/24615/248
Abdominal Pain UpperGastrointestinal disorders5/24613/248
DiarrhoeaGastrointestinal disorders8/24611/248
Vaginitis BacterialInfections and infestations8/2465/248
Vulvovaginal Mycotic InfectionInfections and infestations5/2464/248

Baseline characteristics

Age Continuous
Age Continuous(years)Doxycycline HyclateVibramycinTotal
Mean24.1 ± 4.923.9 ± 4.924.0 ± 4.9
Age, Customized
Age, Customized(participants)Doxycycline HyclateVibramycinTotal
<30 years163170333
Between 30 and 40 years221840
>40 years325
Gender
Gender(participants)Doxycycline HyclateVibramycinTotal
Female115118233
Male7372145
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Doxycycline HyclateVibramycinTotal
Hispanic or Latino334477
Not Hispanic or Latino155146301
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Doxycycline HyclateVibramycinTotal
American Indian or Alaska Native213
Asian314
Native Hawaiian or Other Pacific Islander314
Black or African American109104213
White6173134
More than one race101020
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Doxycycline HyclateVibramycinTotal
United States247248495
08

Study locations

43 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Foley, Alabama 36535, United States
  • Research Site
    Tucson, Arizona 85710, United States
  • Research Site
    Anaheim, California 92805, United States
  • Research Site
    Fresno, California 93726, United States
  • Research Site
    Los Angeles, California 90007, United States
  • Research Site
    San Diego, California 92108, United States
  • Research Site
    Boca Raton, Florida 33432, United States
  • Research Site
    Boynton Beach, Florida 33472, United States
  • Research Site
    Margate, Florida 33063, United States
  • Research Site
    North Miami, Florida 33161, United States
  • Research Site
    South Miami, Florida 33143, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Decatur, Georgia 30033, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Chicago, Illinois 60613, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Arkansas City, Kansas 67005, United States
  • Research Site
    Newton, Kansas 67114, United States
  • Research Site
    Wichita, Kansas 67207, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    New Orleans, Louisiana 70115, United States
  • Research Site
    Fall River, Massachusetts 02720, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Jackson, Mississippi 39213, United States
  • Research Site
    Las Vegas, Nevada 89106, United States
  • Research Site
    Las Vegas, Nevada 89109, United States
  • Research Site
    North Las Vegas, Nevada 89030, United States
  • Research Site
    Brooklyn, New York 11203, United States
  • Research Site
    Greensboro, North Carolina 27405, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Raleigh, North Carolina 27612, United States
  • Research Site
    Columbus, Ohio 43231, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Jefferson Hills, Pennsylvania 15025, United States
  • Research Site
    Jenkintown, Pennsylvania 19046, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Norfolk, Virginia 23507, United States
  • Research Site
    Spokane, Washington 99207, United States
  • Research Site
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Geisler WM, Koltun WD, Abdelsayed N, Burigo J, Mena L, Taylor SN, Batteiger BE, Thurman AR, Hook EW 3rd, Vaughn TA, Annett MP, Muenzen RA, Caminis J. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis. 2012 Jul;55(1):82-8. doi: 10.1093/cid/cis291. Epub 2012 Mar 19. PubMed 22431798 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2010
First posted
Apr 30, 2010
Start
Apr 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Jan 27, 2012
Last update
Jan 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01113931
Lead sponsor
Warner Chilcott
Responsible party
Sponsor
First posted
Apr 30, 2010
Start date
Apr 2010
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Jan 27, 2012
Last update
Jan 27, 2012

Study contacts

John Caminis, MD
study director · Warner Chilcott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion